Therapy for recurrent malignant glioma in adults

Expert Review of Anticancer Therapy

Volumn 4, Issue 5, 2004, Pages 759-782

  Mrugala, Maciej M ^a,b   Kesari, Santosh ^a,b   Ramakrishna, Naren ^c   Wen, Patrick Y ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiogenesis; Chemotherapy; Gene therapy; Immunotherapy; Malignant glioma; Radiation therapy; Targeted molecular therapy

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; DEPSIPEPTIDE; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; GEFITINIB; IMATINIB; IRINOTECAN; LAPATINIB; LENALIDOMIDE; LOMUSTINE; LONAFARNIB; MELPHALAN; OXALIPLATIN; PACLITAXEL; PROCARBAZINE; RAPAMYCIN; TACROLIMUS; TAMOXIFEN; TEMOZOLOMIDE; THALIDOMIDE; TIPIFARNIB; UNINDEXED DRUG; VATALANIB; VINCRISTINE; VORINOSTAT;

CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG ERUPTION; DRUG MECHANISM; DRUG PENETRATION; ERYTHEMA; FATIGUE; GLIOBLASTOMA; HEADACHE; HUMAN; LUNG TOXICITY; NAUSEA; NEUTROPENIA; RADIOSURGERY; RECEPTOR BLOCKING; RECURRENT CANCER; REVIEW; STEREOTAXIC SURGERY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 5444269248     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.5.759     Document Type: Review

References (222)

1. Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1995-1999. Central Brain Tumor Registry of the United States (2002).
2. Kleihues P, Cavenee WK. World Health Organization Classification of Tumors: Pathology and Genetics of Tumours of the Nervous System. IARC Press, Lyon, France (2000).
3. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY. Primary brain tumors in adults. Lancet 361, 323-331 (2003).
4. Stupp R, Mason WP, Van Den Bent MJ et al. Concomitant and adjuvant temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme. Conclusive results of a Randomized Phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 2).
5. Stupp R, Dietrich P-Y, Kraljevic SO et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol. 20, 1375-1382 (2002).
6. Brandes AA. State-of-the-art treatment of high-grade brain tumors. Semin. Oncol. 30, 4-9 (2003).
7. Stupp R, Regg C. New drugs and combinations for malignant glioma. Forum (Genova) 13, 61-75 (2003).
8. Fine HA, Dear KBG, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71, 2585-2597 (1993).
9. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet 359, 1011-1018 (2002).
10. Van Rijn J, Heimans JJ, van der Berg J et al. Survival of human glioma cells treated with various combinations of temozolomide and x-rays. Int. J. Radiat. Oncol. Biol. Phys. 47, 779-784 (2000).
11. Westphal M, Hilt DC, Bortey E et al. A Phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel® wafers) in patients with primary malignant glioma. Neurooncology 5, 79-88 (2003).
12. Levin VA, Leibel SA, Gutin PH. Neoplasms of the central nervous system. In: Cancer: Principles & Practice of Oncology. DeVita VT, Hellman S, Rosenberg SA (Eds), Lippincott Williams & Wilkins, PA, USA, 2100-2103 (2001).
13. Galanis E, Buckner JC. Chemotherapy for high-grade gliomas. Br. J. Cancer 82, 1371-1380 (2000).
14. Nieder C, Grosu AL. Molls M. A comparison of treatment results for recurrent malignant gliomas. Cancer Treat. Rev. 26, 397-409 (2000).
15. Tatter SB. Recurrent malignant glioma in adults. Curr. Treat. Options Oncol. 23, 509-24 (2002).
16. Wen PY, Kesari S. Malignant gliomas. Curr. Neurol. Neurosci. Rep. 4, 218-227 (2004).
17. Barker FG II, Chang SM, Gutin PH et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 42, 709-720 (1998).
18. Keles GE, Lamborn KR, Chang SM, Prados MD, Berger MS. Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastoma multiforme who are undergoing chemotherapy. J. Neurosurg. 100, 41-46 (2004).
19. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 30, 907-911 (1980).
20. Kim HK, Thornton AF, Greenberg HS et al. Results of re-irradiation of primary intracranial neoplasms with three-dimensional conformal therapy. Am. J. Clin. Oncol. 20, 358-363 (1997).
21. Hayat K, Jones B, Bisbrown G et al. Retreatment of patients with intracranial gliomas by external beam radiotherapy and cytotoxic chemotherapy. Clin. Oncol. (R. Coll. Radiol.) 9, 158-163 (1997).
22. Landy HJ, Feun L, Schwade JG et al. Retreatment of intracranial gliomas. South Med. J. 87, 211-214 (1994).
23. Fiveash JB, Spencer SA. Role of radiation therapy and radiosurgery in glioblastoma multiforme. Cancer J. 9, 222-229 (2003).
24. McDermott MW, Sneed PK, Gutin PH. Interstitial brachytherapy for malignant brain tumors. Semin. Surg. Oncol. 14, 79-87 (1998).
25. Shrieve DC, Alexander E III, Wen PY et al. Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 36, 275-282 (1995 ).
26. Florell RC, Macdonald DR, Irish WD et al. Selection bias, survival and brachytherapy for glioma. J. Neurosurg. 76, 179-183 (1992).
27. Selker RG, Shapiro WR, Burger P et al. The Brain Tumor Co-operative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery 51, 343-355 (2002).
28. Patel S, Breneman JC, Warnick RE et al. Permanent iodine-125 interstitial implants for the treatment of recurrent glioblastoma multiforme. Neurosurgery 46, 1123-1128 (2000).
29. Larson DA, Suplica JM, Chang SM et al. Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neurooncology 6, 119-126 (2004).
30. 125I radiation source (GliaSite® Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial. J. Neurosurg. 99, 297-303 (2003).
31. Papagikos MA, Rossi PJ, Bartley A et al. Results of stereotactic radiosurgery and Gliasite® brachytherapy for recurrent glioblastoma multiforme. Neurooncology 5, 344 (2003) (Abstract RT-08).
32. Roberge D, Souhami L. Stereotactic radiosurgery in the management of intracranial gliomas. Technol. Cancer Res. Treat. 2, 117-125 (2003).
33. Cho KH, Hall WA, Gerbi BJ et al. Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int. J. Radiat. Oncol. Biol. Phys. 45, 1133-1141 (1999).
34. Hall WA, Djalilian HR, Sperduto PW et al. Stereotactic radiosurgery for recurrent malignant gliomas. J. Clin. Oncol. 13, 1642-1648 (1995).
35. Larson DA, Prados M, Lamborn KR et al. Phase II study of high central dose gamma knife radiosurgery and marimastat in patients with recurrent malignant glioma. Int. J. Radiat. Oncol. Biol. Phys. 54, 1397-1404 (2002).
36. Barth RF. A critical assessment of boron neutron capture therapy: an overview. J. Neurooncol. 62, 1-5 (2003).
37. Busse PM, Harling OK, Palmer MR et al. A critical examination of the results from the Harvard-MIT NCT program Phase I clinical trial of neutron capture therapy for intracranial disease. J. Neurooncol. 62, 111-121 (2003).
38. Zalutsky MR. Targeted radiotherapy of brain tumors. Br. J. Cancer 90, 1469-1473 (2004).
39. 131I-labeled antitenascin monoclonal antibody 81c6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. 20, 1389-1397 (2002).
40. Prados M. Temozolomide in combination with other cytotoxic agents. Semin. Oncol. 28, 24-33 (2001).
41. Rosenthal MA, Ashley DL, Cher L. BCNU as second line therapy for recurrent high-grade glioma previously treated with temozolomide. J. Clin. Neurosci. 11, 374-375 (2004).
42. Kappelle AC, Postma TJ, Taphoorn MJ et al. PCV chemotherapy for recurrent glioblastoma multiforme. Neurology 56, 118-120 (2001).
43. Newton HB, Junck L, Bromberg J, Page MA, Greenberg HS. Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology 40, 1743-1746 (1990).
44. Jeremic B, Grujicic D, Jevremovic S et al. Carboplatin and etoposide regimen for recurrent malignant glioma: a Phase II study. J. Clin. Oncol. 10, 1074-1077 (1992).
45. Chamberlain MC, Tsao-Wei DD. Salvage chemotherapy with cyclophosphamide for recurrent, temozolomide-refractory glioblastoma multiforme. Cancer 100, 1213-1220 (2004).
46. Fulton D, Urtasun R, Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J. Neurooncol. 27, 149-155 (1996).
47. Basso U, Lonardi S, Brandes AA. Is intra-arterial chemotherapy useful in high-grade gliomas? Expert Rev. Anticancer Ther. 2, 507-519 (2002).
48. Brandes AA, Palmisano V, Pasetto LM, Basso U, Monfardini S. High-dose chemotherapy with bone marrow rescue for high-grade gliomas in adults. Cancer Invest. 19, 41-48 (2003).
49. Abrey LE, Childs BH, Paleologos N et al. High-close chemotherapy with stem cell rescue for anaplastic oligodendroglioma. J. Neurooncol. 65, 127-134 (2003).
50. Robins HI, Chang SM, Prados MD et al. A Phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neurooncology 4, 109-114 (2002).
51. Prados MD, Schold SC, Fine HA et al. A randomized, double-blind, placebo-controlled Phase II study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neurooncology 5, 96-103 (2003).
52. Hochberg F, Prados M, Russell C et al. Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A Phase I-II study. J. Neurooncol. 32, 45-55 (1997).
53. Buckner JC, Brown LD, Kugler JW et al. Phase II evaluation of recombinant interferon-α and BCNU in recurrent glioma. J. Neurosurg. 82, 430-435 (1995).
54. Yung WKA. Temozolomide in malignant gliomas. Semin. Oncol. 27, 27-34 (2000).
55. Dinnes J, Cave C, Huang S, Milne R. A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. Br. J. Cancer 86, 501-505 (2002).
56. Yung WYK, Prados MD, Yaya TR et al. Multicenter. Phase II trial of temozolomide in patients with anaplastic astrocytomas or anaplastic oligoastrocytoma at first relapse. J. Clin. Oncol. 17, 2762-2771 (1999).
57. Yung WYK, Albright RE, Olson J et al. A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 83, 589-593 (2000).
58. Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto Phase II clinical trials. J. Clin. Oncol. 17, 2572-2578 (1999).
59. Osoba D, Brada M, Yung WK, Prados MD. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur. J. Cancer 36, 1788-1795 (2000).
60. Khan RB, Raizer JJ, Malkin MG, Bazylewicz KA, Abrey LE. A Phase II study of extended low-dose temozolomide in recurrent malignant gliomas. Neurooncology 4, 39-43 (2002).
61. Newlands ES, Foster T, Zaknoen S. Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. Br. J. Cancer 89, 248-251 (2003).
62. Korones DN, Benita-Weiss M, Coyle TE et al. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer 97, 1963-1968 (2003).
63. Gilbert M, Wen P, Lieberman F et al. Phase I/II study of combination temozolomide (TMZ) and irinotecan (CPT-11) for recurrent malignant gliomas: a North American Brain Tumor Consortium (NABTC) study. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 410).
64. Gruber ML, Buster WP. Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am. J. Clin. Oncol. 27, 33-38 (2004).
65. Prados MD, Yung WKY, Fine HA et al. Phase II study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium Study. Neurooncology 6, 33-37 (2004).
66. Jaeckle KA, Hess KF, Yung WK et al. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium Study. J. Clin. Oncol. 21, 2305-2311 (2003).
67. Groves MD, Puduvalli VK, Hess KR et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol. 20, 1383-1388 (2002).
68. Silvani A, Eoli M, Salmaggi A et al. Phase II trial of cisplatin plus temozolomide in recurrent and progressive malignant glioma patients. J. Neurooncol. 66, 203-208 (2004).
69. Brandes AA, Basso U, Reni M et al. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a Phase II study of the Gruppo Italiano Co-operativo di Neuro-Oncologia. J. Clin. Oncol. 22, 1598-1604 (2004).
70. Chua SL, Rosenthal MA, Wong SS et al. Phase II study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme. Neurooncology 6, 38-43 (2004).
71. Batchelor TT, Gilbert MR, Supko JG et al. Phase II study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neurooncology 6, 21-27 (2004).
72. Houghton PJ, Cheshire PJ, Hallman JD et al. Efficacy of the topoisomerase I inhibitors topotecan and irinotecan, administered in low doses in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother. Pharmacol. 36, 393-403 (1995).
73. Buckner JC, Reid JM. Wright K et al. Irinotecan in the treatment of glioma patients. Current and future treatments of the North Central Cancer Treatment Group. Cancer 97(Suppl. 9), 2352-2358 (2003).
74. Friedman HS, Petros WP, Friedman AH et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J. Clin. Oncol. 17, 1516-1525 (1999).
75. Prados MD, Yung WYK, Jaeckle KA et al. Phase I trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neurooncology 6, 44-54 (2004).
76. Gilbert MR, Supko JG, Batchelor T et al. Phase I clinical trial and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin. Cancer Res. 9, 2940-2949 (2003).
77. Raymond E, Fabbro M, Boige V et al. Multicenter Phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastomas. Ann. Oncol. 14, 603-614 (2003).
78. Cloughesy TF, Filka E, Kuhn J et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen Cancer 1, 97(Suppl. 9), 2381-2386 (2003).
79. Parker RJ, Fruehauf JP, Mehta F, Filka E, Cloughesy T. A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma. J. Neurooncol. 66, 365-375 (2004).
80. Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J. Neurooncol. 56, 183-188 (2002).
81. Reardon DA, Quinn JA, Rich JN et al. Phase II trial of BCNU plus irinotecan in adults with malignant glioma. Neurooncoly 6, 134-144 (2004).
82. Jendrossek V, Belka C, Bamberg M. Novel chemotherapeutic agents for the treatment of glioblastoma multiforme. Expert Opin. Invest. Drugs 12, 1899-1924 (2003).
83. Parney IF, Chang SM. Current chemotherapy for glioblastoma. Cancer J. 9, 149-156 (2003).
84. Weller M, Muller B, Koch R et al. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. J. Clin. Oncol. 21, 3276-3284 (2003).
85. Hau P, Fabel K, Baumgart U et al. Pegylated liposomal doxorubicin - efficacy in patients with recurrent high-grade glioma. Cancer 100, 1199-1207 (2004).
86. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann. Neurol. 23, 360-364 (1988).
87. Cairncross JG, Macdonald DR, Ludwin S et al. Chemotherapy for oligodendroglioma. J. Clin. Oncol. 12, 2013-2021 (1994).
88. Soffietti R. Chemotherapy of anaplastic oligodendroglial tumours. Expert Opin. Pharmacother. 5, 295-306 (2004).
89. Glass J, Hochberg FH, Gruber ML, Louis DN, Smith D, Rattner B. The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J. Neurosurg. 76, 741-745 (1992).
90. Van Den Bent MJ. Guidelines for the treatment of oligodendroglioma: an evidence-based medicine approach. Forum (Genova 13, 18-31 (2003).
91. Paleologos NA, Cairncross JG. Treatment of oligodendrogliomas: an update. Neurooncology 1, 61-68 (1999).
92. van den Bent M, Chinot OL, Cairncross JG. Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neurooncology 5, 128-38 (2003).
93. Chinot O, Honore S, Barre M et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J. Clin. Oncol. 19, 2449-2455 (2001).
94. Van den Bent MJ, Chinot O, Boogerd W et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomusting and vincristine) chemotherapr. EORTC Brain Tumor Group Phase II study of 26972. Ann. Oncol. 14, 599-602 (2003).
95. Van den Bent MJ, Taphoorn MJB, Brandes AA et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglioma tumors: European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J. Clin. Oncol. 13, 2525-2528 (2003).
96. Cairncross JG, Ueki Y, Zlatescu MC et al. Specific chromosomal losses predict chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl Cancer Inst. 90, 1473-1479 (1998).
97. Ino Y, Betensky RA, Zlatescu MC et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin. Cancer Res. 7, 839-845 (2001).
98. Brandes AA, Turazzi S, Basso U et al. A multidrug combination designed for reversing resistance to BCNU in glioblastoma multiforme. Neurology 58, 1759-1764 (2002).
99. 6-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J. Clin. Oncol. 20, 2277-2283 (2002).
100. Gururangan S, Cokgor L, Rich JN et al. Phase I study of Gliadel® wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neurooncology 3, 246-250 (2001 ).
101. Westphal M, Lamszus K, Hilt D. Intracavitary chemotherapy for glioblastoma: present status and future directions. Acta Neurochir. Suppl. 88, 61-67 (2003).
102. Guerin G, Olivi A, Weingart JD et al. Recent advances in brain tumor therapy: local intracerebral drug delivery by polymers. Invest. New Drugs 22, 27-37 (2004).
103. Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent malignant gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345, 1008-1012 (1999).
104. Olivi A, Grossman SA, Tatter S et al. Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches To Brain Tumor Therapy CNS Consortium trial. J. Clin. Oncol. 21, 1845-1849 (2003).
105. Hassenbusch SJ, Nardone EM, Levin VA, Leeds N, Pietronigro D. Stereotactic injection of DTI-015 into recurrent malignant gliomas: Phase I/II trial. Neoplasia 5, 9-16 (2003).
106. Lidar Z, Mardor Y, Jonas T et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a Phase I/II clinical study. J. Neurosurg. 100, 472-479 (2004).
107. Menei P, Jadaud E, Faisant N et al. Stereotaxic implantation of 5-flurouracil-releasing microspheres in malignant glioma. A Phase I study. Cancer 100, 405-410 (2004).
108. Husain SR, Puri RK. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J. Neurooncol. 65, 37-48 (2003).
109. Kunwar S, Prados M, Chang S et al. Peritumoral convection-enhanced delivery of IL-13-PE38QQR in patients with recurrent malignant glioma - Phase I interim results. Neurooncology 5, 350 (2003) (Abstract TA-15).
110. Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing Phase I studies. Acta Neurochir. Suppl. 88, 105-111 (2003).
111. Weber FW, Floeth F, Asher A. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir. Suppl. 88, 93-103 (2003).
112. Kawakami M, Kawakami K, Puri RK. Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy. J. Neurooncol. 65 (1), 15-25 (2003).
113. Weber F, Asher A, Bucholz R et al. Safety, tolerability, and tumor response of IL-4 Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J. Neurooncol. 64, 125-137 (2003).
114. Sampson JH, Akabanai G, Archer GE et al. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J. Neurooncol. 65, 27-35 (2003).
115. 131I-TM-601 in adult patients with recurrent high-grade-glioma. Neurooncology 5, 340 (2003) (Abstract RA-19 ).
116. Maher EA, Furnari FB, Bachoo RM et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 15(11), 1311-1333 (2001).
117. Kitange GJ, Templeton KL, Jenkins RB. Recent advances in the molecular genetics of primary gliomas. Curr. Opin. Oncol. 15(3), 197-203 (2003).
118. Konopka G, Bonni A. Signaling pathways regulating gliomagenesis. Curr. Mol. Med. 3(1), 73-84 (2003).
119. van den Boom J, Wolter M, Kuick R et al. Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am. J. Pathol. 163, 1033-1043 (2003).
120. Mischel PS, Nelson SF, Cloughesy TF. Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol. Ther. 2, 242-247 (2003).
121. Rao RD, Uhm JH, Krishnan S, James CD. Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies. Front. Biosci. 8, 270-280 (2003).
122. Shai R. Shi T, Kremen TJ et al. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 22, 4918-4923 (2003).
123. Nutt CL, Mani DR, Betensky RA et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 63, 1602-1607 (2003).
124. Drucker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell 1, 31-36 (2002).
125. Karpati G, Nalbantoglu J. The principles of molecular therapies for glioblastoma. Int. Rev. Neurobiol. 55, 151-163 (2003).
126. Newton HB. Molecular neuro-oncology and the development of 'targeted' therapeutic strategies for brain tumors. Part 1 - growth factor and Ras signaling pathways. Expert Rev. Anticancer Ther. 3, 595-614 (2003).
127. Newton HB. Molecular neurooncology and the development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev. Anticancer Ther. 4, 105-128 (2004).
128. Mischel PS, Cloughesy TF. Targeted molecular therapy of glioblastoma. Brain Pathol. 13, 52-61 (2003).
129. Rich JN, Bigner DD. Development of novel targeted therapies in the treatment of malignant glioma. Nature Rev. Drug Discov. 3, 430-446 (2004).
130. Tremont-Lukats IW, Gilbert MP, Advances in molecular therapies in patients with brain tumors. Cancer Control 10, 125-137 (2003).
131. Jendrossek V, Belka C, Bamberg M. Novel chemotherapeutic agents for the treatment of glioblastoma multiforme. Expert Opin. Invest. Drugs 12, 1899-1924 (2003).
132. Rich J, Reardon DA, Peery TS et al. Phase II trial of ZD 1839 for patients with first relapse glioblastoma. J. Clin. Oncol. 22, 133-142 (2004).
133. Shinojima N, Tada Y, Shiraishi S et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 63, 6962-6970 (2003).
134. Lieberman F, Cloughesy T, Deangelis LM et al. Phase I-II study of ZD-1839 for recurrent malignant gliomas and meningiomas progressing after radiation therapy. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 1510).
135. Uhm JH, Ballman KV, Giannini JC et al. Phase II study of ZD1839/Iressa® in patients with newly diagnosed grade 4 astrocytoma. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 1505).
136. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004)
137. Raizer JJ, Abrey L, Wen P et al. A Phase II trial of OSI-774 (Tarceva) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 1502).
138. Prados M, Chang S, Burton E et al. Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma. Proc. Am. Soc. Clin. Oncol. (2003) (Abstract 394).
139. Vogelbaum MA, Peereboom D, Stevens G et al. Phase II trial of the EGFR tyrosine kinase inhibitor erlotinib for single agent therapy of recurrent glioblastoma multiforme: interim results. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 1558).
140. Goudar R, Keir S, Hjelmeland M et al. Combination therapy of inhibitors of the epidermal growth factor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma growth inhibition. AACR-NCI-EORTC Int. Conf. Mol. Targets Cancer Ther. (2003) (Abstract A88).
141. Guha A, Dashner K, Black PM et al. In vivo expression of PDGF and PDGF receptors in human astrocytomas. Int. J. Cancer 60, 168-173 (1995).
142. Kilic T, Alberta J, Zdunek PR et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally-active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 60, 5143-5150 (2000).
143. Wen PY, Yung WK, Hess K et al. Phase I study of STI571 (Gleevec) for patients with recurrent malignant gliomas and meningiomas (NABTC 99-08). Proc. Am. Soc. Clin. Oncol. 73a (2002) (Abstract 291).
144. Raymond E, Brandes A, Van Oosterom AV et al. Multicentre Phase II study of imatinib mesylate (Glivec®) in patients with recurrent glioblastoma: an EORTC/ NDDG/BTG Intergroup study. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 1501).
145. Dai H, Marbach P, Lemaire M et al. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J. Pharmarcol. Exp. Ther. 304, 1085-1092 (2003).
146. Dresemann G. Imatinib (STI571) plus hydroxyurea: safety and efficacy in pretreated, progressive glioblastoma multiforme (GBM) patients (pts). Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 1550 ).
147. de Bono JS, Tolcher AW, Rowinsky EK. Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma. Semin. Oncol. 30(5 Suppl. 16), 79-92 (2003).
148. Cloughesy TF, Kuhn J, Wen P et al. Two Phase II trials of R115777 (Zarnestra®) in patients with recurrent glioblastoma multiforme: a comparison of patients on enzyme-inducing antiepileptic drugs (EIAED) and not on EIAED at maximum tolerated dose respectively: a North American Brain Tumor Consortium (NATC) report. Neurooncology 5, 349 (2003) (Abstract TA-10).
149. Mita NUA, Mita A, Rowinsky EY, The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol. Ther. 2(4 Suppl. 1), S169-S177 (2003).
150. Geoerger B, Kerr K, Tang C-B et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res. 61, 1527-1532 (2001).
151. Chang S, Kuhn J, Wen P et al. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest. New Drugs 22(4), 427-435 (2004).
152. Chang S, Kuhn J, Wen P et al. Phase II/pharmacokinetic study of CCI-779 in recurrent glioblastoma multiforme. Society for Neuro-Oncology 8th annual meeting. Neurooncology 5, 349 (2003) (Abstract TA-09).
153. Galanis E, Buckner JC, Maurer K et al. NCCTG Phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM). Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 1503).
154. Readon D, Friedman H, Yung WKA et al. A Phase I trial of PTK787/ZK 222584 (PTK/ZK), an oral VEGF tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 1513).
155. Marks PA, Rifkind RA, Richon VM et al. Histone deacetylases and cancer: causes and therapies. Nature Cancer Rev. 1, 194-202 (2001).
156. Rubin JB, Kung AL, Klein RS et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc. Natl Acad Sci. 100, 13513-13518 (2003).
157. Guzman M. Cannabinoids: potential anticancer agents. Nature Rev. Cancer 3, 745-755 (2003).
158. Sanchez C, de Ceballos ML, del Pulgar TG et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res. 61, 5784-5789 (2001).
159. Choe G, Horvath S, Cloughesy TF et al. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 63, 2742-2746 (2003).
160. Tjuvajev JG, Blasberg R. In vivo imaging of molecular-genetic targets for cancer therapy. Cancer Cell 3, 327-332 (2003).
161. Kieran MW, Billett A. Anti-angiogenesis therapy. Current and future agents. Hematol. Oncol. Clin. North Am. 15, 835-851 (2001).
162. Bogler O, Mikkelsen T. Angiogenesis in glioma: molecular mechanisms and roadblocks to translation. Cancer J. 9, 205-213 (2003).
163. Keran MW. Anti-angiogenic chemotherapy in central nervous system tumors. Cancer Treat. Res. 117, 337-349 (2004).
164. Castro MG, Cowen R, Williamson IK. Current and future strategies for the treatment of malignant brain tumors. Pharmacol. Ther. 98, 71-108 (2003).
165. Basso U, Ermani M, Vastola F, Brandes AA. Non-cytotoxic therapies for malignant gliomas. J. Neurooncol. 58, 57-68 (2002).
166. Fine HA, Figg WD, Jaeckle K et al. Phase II trial of the anti-angiogenic agent thalidomide in patients with recurrent high-grade gliomas. J. Clin Oncol. 18, 708-715 (2000).
167. Marx GM, Pavlakis N, McCowatt S et al. Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J. Neurooncol. 54, 31-38 (2001).
168. Short SC, Traish D, Dowe A, Hines F, Gore M, Brada M. Thalidomide as an anti-angiogenic agent in relapsed gliomas. J. Neurooncol. 51, 41-45 (2001).
169. Fine HA, Wen PY, Maher EA et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade-gliomas. J. Clin. Oncol. 21, 2299-2304 (2003).
170. Groves MD, Tremont-Lukats IW, Conrad C et al. A Phase II trial of temozolomide plus thalidomide (NABTC 99-04) for recurrent malignant glioma. Proceedings of the 5th Congress of the European Association for Neuro-Oncology. Neurooncology 4, S41 (2002).
171. Fine HA, Kim L, Royce C et al. A Phase II trial of LY317615* in patients with recurrent high grade gliomas. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 1511).
172. Jones MK, Wang H, Peskar BM et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nature Med. 5, 1418-1423 (1999).
173. Masferrer JL, Leahy KM, Koki AT et al. Anti-angiogenic and antitumor activities of cyclooxygenaase-2 inhibitors. Cancer Res. 60, 1306-1311 (2000).
174. Joki T, Heese O, Nikas DC et al. Expression of cyclooxygenase-2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res. 60, 4926-4931 (2000).
175. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 61, 4375-4381 (2001).
176. Giglio P, Levin V. Cyclooxygenase-2 inhibitors in glioma therapy. Am. J. Ther. 11, 141-143 (2004).
177. Badie B, Schartner JM, Hagar AR et al. Microglia cyclooxygenase-2 activity in experimental gliomas: possible role in cerebral edema formation. Clin. Cancer Res. 9, 872-877 (2003).
178. Lamszus K, Kunkel P, Westphal M. Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir. Suppl. 88, 169-177 (2003).
179. Chatterjee S, Matsumura A, Schradermeier J, Gillespie GY. Human malignant glioma therapy using anti-α(v)β3 integrin agents. J. Neurooncol. 46, 135-144 (2000).
180. MacDonald TJ, Taga T, Shimada H et al. Preferential susceptibility of brain tumors to the anti-angiogenic effects of an
181. Browder T, Butterfield CE, Kraling BM et al. Anti-angiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60, 1878-1886 (2000).
182. Wen PY, Schiff D, MacDonald L et al. Phase II study of anti-angiogenic chemotherapy for recurrent malignant glioma. Neurooncology 4, 357 (2004) (Abstract TA 42).
183. See SJ, Levin VA, Yung WK, Hess KR, Groves MD. 13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme. Neurooncology 6(3), 253-258 (2004).
184. Yung WYK, Kyritsis AP, Gleason MJ, Levin VA. Treatment of recurrent malignant gliomos with high-dose 13 cis-retinoic acid. Clin. Cancer Res. 2, 1931-1935 (1996).
185. Puduvalli VK, Yung WKA, Hess KR et al. A Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: a North American Brain Tumor Consortium (NABTC) study. J. Clin. Oncol. (2004) (In Press).
186. Chang SM, Kuhn JG, Ian Robins H et al. A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors consortium report. Invest. New Drugs. 21, 429-433 (2003).
187. Couldwell WT, Weiss MH, DeGiorgio CM et al. Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 32, 485-489 (1993).
188. Chamberlain MC, Kormanik PA. Salvage chemotherapy with tamoxifen for recurrent anaplastic astrocytomas. Arch. Neurol. 56, 703-708 (1999).
189. Hercbergs AA, Goyal LK, Suh JH et al. Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a Phase I/II study. Anticancer Res. 23, 617-626 (2003).
190. Rainov NG, Ren H. Clinical trials with retrovirus mediated gene therapy - what have we learned? J. Neurooncol. 65, 227-236 (2003).
191. Shah AC, Benos D, Yancey Gillespie G, Markert JM. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J. Neurooncol. 65, 203-226 (2003).
192. Vecil GG, Lang FE. Clinical trials of adenoviruses in brain tumors: a review of Ad-p53 and oncolytic adenoviruses. J. Neurooncol. 65, 237-246 (2003).
193. Laura K, Aguilar LK, Aguilar-Cordova E. Evolution of a gene therapy clinical trial. From bench to bedside and back. J. Neurooncol. 65, 307-315 (2003).
194. Kanzawa T, Ito H, Kondo Y, Kondo S. Current and future gene therapy for malignant gliomas. J. Biomed Biotech. 1, 25-34 (2003).
195. Rainov NG, Ren H. Gene therapy for human malignant brain tumors. Cancer J. 9, 180-188 (2003).
196. Post DE, Fulci G, Chiocca EA, Van Meir EG. Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr. Gene Ther. 4, 41-51 (2004).
197. Ram Z, Culver KW, Oshiro EM et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nature Med. 12, 1354-1361 (1997).
198. Prados MD, McDermott M, Chang SM et al. Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: a Phase I/II multi-institutional trial. J. Neurooncol. 65, 269-278 (2003).
199. Smitt PS, Driesse M, Wolbers J, Kros M, Avezaat C. Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol. Ther. 7, 851-858 (2003).
200. Germano IM, Fable J, Gultekin SH, Silvers A. Adenovirus/herpes simplex-thymidine kinase/ganciclovir complex: preliminary results of a Phase I trial in patients with recurrent malignant gliomas. J. Neurooncol. 65(3), 279-89 (2003).
201. Lang FF, Bruner JM, Fuller GN et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J. Clin. Oncol. 21, 2505-2518 (2003).
202. Lichtor T, Glick RP. Cytokine immunogene therapy for treatment of brain tumors. J. Neurooncol. 65, 247-259 (2003).
203. Eck SL, Alavi JB, Judy K et al. Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-β (H5.010CMVhIFN-β): a Phase I trial. Human Gene Ther. 12, 97-113 (2001).
204. Markert JM, Medlock MD, Rabkin SD et al. Conditionally replicating herpes simplex virus mutant, G207, for the treatment of malignant glioma: results of a Phase I trial. Gene Ther. 7, 867-874 (2000).
205. Wilcox ME, Yang W, Senger D et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J. Natl Cancer Inst. 93, 903-912 (2001).
206. Yang L, Ng KY, Lillehei KO. Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer Control 10, 138-147 (2003).
207. Fecci PE, Sampson JH. Clinical immunotherapy for brain tumors. Neuroimaging Clin. N. Am. 12, 641-664 (2002).
208. Fecci PE, Mitchell DA, Archer GE et al. The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. J. Neurooncol. 64, 161-176 (2003).
209. Paul DB, Kruse CA. Immunologic approaches to therapy for brain tumors. Curr. Neurol. Neurosci. Rep. 1, 238-244 (2001).
210. Fenstermaker RA, Ciesielski MJ. Immunotherapeutic strategies for malignant: glioma. Cancer Control 11, 181-191 (2004).
211. Ehtesham M, Black KL, Yu JS. Recent progress in immunotherapy for malignant glioma: treatment strategies and results from clinical trials. Cancer Control 11, 192-197 (2004).
212. Goetz C, Riva P, Poepperl G et al. Locoregional radioimmunotherapy in selected patients with malignant glioma: experiences, side effects and survival times. J Neurooncol. 62, 321-328 (2003).
213. 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas. Int. J. Radiat. Oncol. Biol. Phys. 58, 972-975 (2004).
214. 90Y-biotin in glioma patients: Phase I study and preliminary therapeutic results. Cancer Biother. Radiopharm. 16, 227-235 (2001).
215. Yamanaka R, Abe T, Yajima N et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical Phase I/II trial. Br. J. Cancer 89, 1172-1179 (2003).
216. Yu JS, Wheeler CJ, Zeltzer PM et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial. T-cell infiltration. Cancer Res. 61, 842-847 (2001).
217. Okada H, Lieberman FS, Edington HD et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J. Neurooncol. 64, 13-20 (2003).
218. Bogdahn U, Hau P, Brawanski A et al. Specific therapy for high-grade glioma by convection-enhanced delivery of the TGF-β2 specific antisense oligonucleotide AP 12009. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 1514).
219. Reni M, Brandes AA. Current management and prognostic factors for adult ependymoma. Expert Rev. Anticancer Ther. 2, 537-545 (2002).
220. Chamberlain MC. Ependymomas. Curr. Neurol. Neurosci. Rep. 3, 193-199 (2003).
221. Moynihan TJ. Ependymal tumors. Curr. Treat. Options Oncol. 4, 517-523 (2003).
222. Prados MD, Yung WKA, Wen P et al. Phase I study of ZD 1839 plus temozolomide in patients with malignant glioma. A study of the North American Brain Tumor Consortium. Proc. Am. Soc. Clin. Oncol. (2004) (Abstract 1504).